Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

NCT05531708 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped The study is not initiated and we want it to be withdrawn.

Conditions

Mesothelin-positive Advanced Refractory Solid Tumors

Interventions

BIOLOGICAL: Anti-mesothelin CAR-T cells
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Shanghai Pudong Hospital

Collaborators

[object Object]